Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas

Journal of Geriatric Oncology

Volumn 5, Issue 4, 2014, Pages 389-399

  Coppola, Domenico ^a   Balducci, Lodovico ^a   Chen, Dung Tsa ^a   Loboda, Andrey ^d   Nebozhyn, Michael ^a,d   Staller, Aileen ^a   Fulp, William J ^a   Dalton, William ^a   Yeatman, Timothy ^a,c   Brem, Steven ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Gibbs Cancer Center   (United States)

^d Merck Laboratory   (United States)

Author keywords

Aging; Astrocytoma; Biomarker; Genomics; Glioblastoma; Interleukin 6; Senescence

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CCL2 GENE; CCL7 GENE; CDKN1A GENE; CELL AGING; CLINICAL ARTICLE; CONTROLLED STUDY; COPG GENE; CSF2RB GENE; CXCL1 GENE; FEMALE; GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ICAM 1 GENE; IGFBP 3 GENE; IL 6 GENE; IL 8 GENE; MALE; MIDDLE AGED; ONSET AGE; SAA4 GENE; SCORING SYSTEM; SENESCENCE; SENESCENCE ASSOCIATED GENE; TNFRSF 11B GENE; TNFSF 11 GENE; TP53 GENE; VERY ELDERLY; AGE; AGING; BRAIN; BRAIN TUMOR; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BRAIN; BRAIN NEOPLASMS; CELL AGING; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84908163037     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2014.08.003     Document Type: Article

References (79)

1. WHO Classification of Tumors of the Central Nervous System 2007, IARC, Lyon. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.).
2. Schwartzbaum J.A., Fisher J.L., Aldape K.D., Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006, 2(9):494-503.
3. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344(2):114-123.
4. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alteration in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64(6):479-489.
5. Brem S., Snodgrass S., Booth-Jones M., et al. Anaplastic astrocytoma. Textbook of Neurooncology 2005, 18:122-142. Elsevier Saunders, Philadelphia. M.D. Prados, M.S. Berger (Eds.).
6. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8(9):729-740.
7. Coppé J.P., Patil C.K., Rodier F., Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-non-autonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6(12):2853-2868.
8. Rodier F., Coppé J.P., Patil C.K., Hoeijmaker WA, Munoz DP, Raza SR, et al. Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11(8):973-979.
9. Coppé J.P., Patil C.K., Rodier F., Krtlica A, Beaujesour CM, Parrinello S, et al. A human-like senescence-associated-secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One 2010, 5(2):e9188.
10. Gosselin K., Martien S., Pourtier A., Vercamer C, Ostoich P, Morat L, et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 2009, 69(20):7917-7925.
11. Kuilman T., Michaloglou C., Mooi W., Peeper D.S. The essence of senescence. Genes Dev 2010, 24(22):2463-2479.
12. Bavik C., Coleman I., Dean J.P., Knudsen B., Plymate S., Nelson P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006, 66(2):794-802.
13. Campisi J., Andersen J.K., Kapahi P., Melov S. Cellular senescence: a link between cancer and age-related degenerative disease?. Semin Cancer Biol 2011, 21(6):354-359.
14. Decottignies A., d'Adda di Fagagna F. Epigenetic alterations associated with cellular senescence: a barrier against tumorigenesis or a red carpet for cancer?. Semin Cancer Biol 2011, 21(6):360-366.
15. Guerra C., Collado M., Navas C., Schuhmacher AJ, Hernandez-porras I, Canamero M, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19(6):728-739.
16. Pernicová Z., Slabáková E., Kharaishvili G., Bouchal J, Krai M, Kunicka Z, et al. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia 2011, 13(6):526-536.
17. Finkel T., Serrano M., Blasco M.A. The common biology of cancer and ageing. Nature 2007, 448(7155):767-774.
18. Davalos A.R., Coppé J.P., Campisi J., Desprez P.Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010, 29(2):273-283.
19. Pazolli E., Luo X., Brehm S., Carbery K, Chung JJ, pryor JL, et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 2009, 69(3):1230-1239.
20. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol Mech Dis 2010, 5:99-118.
21. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
22. Yeatman T.J. A public/private partnership in personalized cancer care. J Med Person. 2011, 9:112-115.
23. Yeatman T.J., Mule J., Dalton W.S., Sullivan D. On the eve of personalized medicine in oncology. Cancer Res 2008, 68(18):7250-7252.
24. Chen D.T., Nasir A., Venkataramu C., Fulp W., Gruidl M., Yeatman T. Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat 2010, 120(1):25-34.
25. Chen D.T., Hsu Y.L., Fulp W.J., Coppola D, Haure E, Yeatman T, et al. Prognostic and predictive value of malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 2011, 103(24):1859-1870.
26. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31(4):e15.
27. Miller R., Siegmund D. Maximally selected Chi square statistics. Biometrics 1982, 48:1011-1016.
28. Shirahata M., Oba S., Iwao-Koizumi K., Saito S, Ueno M, Oda N, et al. Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci 2009, 100(1):165-172.
29. Lausen B., Schumacher M. Evaluating the effect of optimized cutoff values in the assessment of prognostic factors. Comput Stat Data Anal 1996, 21:307-326.
30. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 57:289-300.
31. Reynés G., Vila V., Martín M., Parada A, Fleitas N, Reganon E, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011, 102(1):35-41.
32. Curran W.J., Scott C.B., Horton J., Nelson JS, weinstein AS, Fishbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85(9):704-710.
33. Gravendeel L.A.M., Kouwenhoven M.C.M., Gevaert O., de Rooi JJ, Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009, 69(23):9065-9072.
34. Phillips H.S., Kharbanda S., Chen R., Forrest WS, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173.
35. Lee Y., Scheck A., Cloughesy T.F., Lai A, Dong J, Farooki AK, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genet Oct. 21 2008, 1:52.
36. Suzuki T., Maruno M., Wada K., Kagawa N, Fujimoto Y, Hashimoto N, et al. Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 2004, 21(1):27-34.
37. Gene Ranker - The Cancer Genome Atlas - Glioblastoma 6000 Accessed 5.28.2012 at. http://cbio.mskcc.org/tcga-generanker/.
38. Piperi C., Samaras V., Levidou G., Kavantzas N, Boviatsis E, Petraki K, et al. Prognostic significance of IL-8, STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine 2011, 55(3):387-395.
39. Lederle W., Depner S., Schnur S., Obermueller E, Catone N, Just A, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer 2010, 128(12):2803-2814.
40. Chang C.Y., Li M.C., Liao S.L., Huang Y.L., Shen C.C., Pan H.C. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 2005, 12(8):930-993.
41. Samaras V., Piperi C., Levidou G., Zisakis A, Levidou G, Themistocleous, et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cycoloxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 2009, 70(6):391-397.
42. Brenner A.V., Butler M.A., Wang S.S., Ruder M, Rothman N, Schulte PA, et al. Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 2007, 28(12):2543-2547.
43. Wang H., Lathia J.D., Wu Q., Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27(10):2393-2404.
44. Saidi A., Hagedorn M., Allain N., Verpelli C, Sala C, Bello L, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 2009, 125(5):1054-1064.
45. Bikfalvi A., Moenner M., Javerzat S., North S., Hagedorn M. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 2011, 39(6):1560-1564.45.
46. Wong E.T., Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Cancer Netw 2008, 6:515-522.
47. Samaras V., Piperi C., Korkolopoulou P., Zisakis A, Levidou G, Themistocleous MS, et al. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem 2007, 304(1-2):343-351.46.
48. Momeny M., Malehmir M., Zakidizaji M., Ghasemi R, Ghadimi H, Shokrgozar MA, et al. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs 2010, 21(3):252-260.
49. Burim R.V., Teixeira S.A., Colli B.O., Peria FM, Tirapelli LF, Marie SK, et al. ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas. Clin Exp Med 2009, 9(2):157-163.
50. Lohr J., Ratliff T., Huppertz A., Ge Y, Dictus C, Ahmadi R, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 2011, 17(13):4296-4308.
51. Bu N., Wu H., Sun B., Zhang C, Zhan R, Zhang S, et al. Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with gliomas. J Neurooncol 2011, 104(3):659-697.
52. Nano R., Capelli E., Argentina F., Facoetti A., Gerzeli G. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumors. Cell Mol Biol 2003, 49(6):999.
53. Zumkeller W., Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001, 54(4):227-229.
54. Santosh V., Arivazhagan A., Sreekanthreddy P., et al. Grade-specific expression of insulin-like growth factor- binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 2010, 19(6):1399-1408.
55. Muller H.L., Oh Y., Gargosky S.E., Wilson K.F., Lehrnbecher T., Rosenfeld R.G. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab 1993, 77(5):1113-1119.
56. Liu C. Serum amyloid a protein in clinical cancer diagnosis. Pathol Oncol Res 2012, 18(2):117-121.
57. Dowling P., Clarke C., Hennessy K., Torralbo-Lopez B, Ballot J, Crown J, et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 2012, 131:911-923.
58. Sung H.J., Ahn J.M., Yoon Y.H., Rhim TY, Park CS, Park JY, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011, 10(3):1383-1395.
59. Wood S.L., Rogers M., Cairns D.A., Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010, 103(1):101-111.
60. Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. J Transl Med 2012, 10:45.
61. Ray A., Dhar S., Ray B.K. Control of VEGF expression in triple-negative breast carcinoma cells by suppression of SAF-1 transcription factor activity. Mol Cancer Res 2011, 9(8):1030-1041.
62. Hagihara K., Nishikawa T., Isobe T., Song J., Sugamata Y., Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004, 314(2):363-369.
63. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
64. Park H.J., Kim B.G., Lee S.J., Heo SH, Kim JY, Kwon TH, et al. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res 2008, 7(3):1138-1150.
65. Wu W.J., Erickson J.W., Lin R., Cerione R.A. The gamma-subunit of the coatomer complex binds Cdc42 to mediate transformation. Nature 2000, 405(6788):800-804.
66. Salminen A., Ojala J., Kaarniranta K., Haapasalo A., Hiltunen M., Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci 2011, 34(1):3-11.
67. Baker D.J., Wijshake T., Tchkonia T., LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16Ink4a - positive senescent cells delay ageing-associated disorders. Nature 2011, 479(7372):232-236.
68. Redmond S.A., Chan J.R. Revitalizing remyelination - the answer is circulating. Science 2012, 336(6078):161-162.
69. Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science 2012, 335(6071):936-941.
70. de Groot J.F., Sulman E.P., Aldape K.D. Multigene sets for clinical application in glioma. J Natl Compr Cancer Netw 2011, 9(4):449-457.
71. van den Boom J., Wolter M., Kuick R., Misek DE, Youkilis AS, Wechsler DS, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2006, 163(3):1033-1043.
72. Niclou S.P., Fack F., Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010, 73(10):1823-1838.
73. Petalidis L.P., Oulas A., Backlund M., Wayland MT, Liu L, Plant K, et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 2008, 7(5):1013-1024.
74. Riddick G., Fine H.A. Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 2011, 7(8):439-450.
75. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 2011, 21(1):107-112.
76. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011, 11(7):503-511.
77. Chen J., McKay R.M., Parada L.F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012, 149(1):36-47.
78. Tan D.S., Thomas G.V., Garrett M.D., Banerji U, de Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009, 15(5):406-420.
79. Shoemaker L.D., Achrol A.S., Sethu P., Steinberg G.K., Chang S.D. Clinical neuroproteomics and biomarkers: from basic research to clinical decision making. Neurosurgery 2012, 70(3):518-525.